Capra Biosciences has been awarded a new $7.5 million two-year project agreement, under which it will leverage its bioreactor platform to demonstrate the manufacture of three active pharmaceutical ingredients to be selected in cooperation with the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. “Biomanufacturing has the potential to manufacture many of the chemicals we use today not only more sustainably, but also where and when...